Skip to content
OpenCapital
Get started

NRX Pharmaceuticals, Inc. NRXP Q3 2025 earnings

Reported November 14, 2025 · Before market open

Revenue$242.0KMiss by $7.3MDiluted EPS-$0.18Miss by $0.07
Revenue estimate$7.5M
EPS estimate-$0.11

Next report

Aug 17, 2026 (in a month)
Revenue estimate$1.7M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$1.1MMiss by $18.4MQ4 2025$983.0KMiss by $6.5M
Q3 2025$242.0KMiss by $7.3M
Q1 2025$2.3MQ4 2024$4.0KMiss by $5.0M

Diluted EPS

Q1 2026-$0.04Beat by $0.01Q4 2025$0.19Beat by $0.28
Q3 2025-$0.18Miss by $0.07
Q1 2025-$0.34Miss by $0.04Q4 2024-$0.30Miss by $0.10Q3 2024-$0.15Beat by $0.66

Ask the moment NRX Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did NRX Pharmaceuticals, Inc. report Q3 2025 earnings?
NRX Pharmaceuticals, Inc. (NRXP) reported Q3 2025 earnings on November 14, 2025 before market open.
What were NRX Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
NRX Pharmaceuticals, Inc. reported revenue of $242.0K and diluted EPS of $-0.18 for Q3 2025.
Did NRX Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $7.5M by $7.3M. EPS missed the consensus estimate of $-0.11 by $0.07.
How did NRX Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 20.0% from $-0.15.
Where can I find NRX Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001437749-25-035210) directly on SEC EDGAR. The filing index links above go to sec.gov.